APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Therapeutics and Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastrointestinal Therapeutics and Diagnostics Market Outlook and Growth Opportunities 2026

21 December 2025197 pages

Choose your research edition.

Industry ResearchGastrointestinal Therapeutics and Diagnostics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Therapeutics and Diagnostics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Therapeutics and Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Therapeutics and Diagnostics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Therapeutics and Diagnostics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Gastrointestinal Therapeutics and Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastrointestinal Therapeutics and Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastrointestinal Therapeutics and Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Therapeutics and Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastrointestinal Therapeutics and Diagnostics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastrointestinal Therapeutics and Diagnostics market include Takeda Pharmaceutical Company, Eisai, Johnson & Johnson, AstraZeneca, Salix Pharmaceuticals and Abbott Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gastrointestinal Therapeutics and Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastrointestinal Therapeutics and Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastrointestinal Therapeutics and Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gastrointestinal Therapeutics and Diagnostics market.

Gastrointestinal Therapeutics and Diagnostics Segment by Company

Takeda Pharmaceutical Company

Eisai

Johnson & Johnson

AstraZeneca

Salix Pharmaceuticals

Abbott Laboratories

Gastrointestinal Therapeutics and Diagnostics Segment by Type

Diagnostics

Therapeutics

Gastrointestinal Therapeutics and Diagnostics Segment by Application

Peptic Ulcer Disease (PUD)

GI Bleeding

Gastroenteritis

Irritable Bowel Syndrome

Others

Gastrointestinal Therapeutics and Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastrointestinal Therapeutics and Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gastrointestinal Therapeutics and Diagnostics key companies, revenue, market share, and recent developments.

3. To split the Gastrointestinal Therapeutics and Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gastrointestinal Therapeutics and Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastrointestinal Therapeutics and Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze Gastrointestinal Therapeutics and Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Therapeutics and Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Therapeutics and Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Therapeutics and Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastrointestinal Therapeutics and Diagnostics industry.

Chapter 3: Detailed analysis of Gastrointestinal Therapeutics and Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gastrointestinal Therapeutics and Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gastrointestinal Therapeutics and Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastrointestinal Therapeutics and Diagnostics Industry Trends Table 2. Gastrointestinal Therapeutics and Diagnostics Industry Drivers Table 3. Gastrointestinal Therapeutics and Diagnostics Industry Opportunities and Challenges Table 4. Gastrointestinal Therapeutics and Diagnostics Industry Restraints Table 5. Global Gastrointestinal Therapeutics and Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastrointestinal Therapeutics and Diagnostics Revenue Share by Company (2021-2026) Table 7. Global Gastrointestinal Therapeutics and Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gastrointestinal Therapeutics and Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global Gastrointestinal Therapeutics and Diagnostics Company, Product Type & Application Table 10. Global Gastrointestinal Therapeutics and Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gastrointestinal Therapeutics and Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Diagnostics Table 15. Significant Companies of Therapeutics Table 16. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type (2021-2026) Table 20. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Peptic Ulcer Disease (PUD) Table 22. Significant Companies of GI Bleeding Table 23. Significant Companies of Gastroenteritis Table 24. Significant Companies of Irritable Bowel Syndrome Table 25. Significant Companies of Others Table 26. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application (2021-2026) Table 30. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application (2027-2032) Table 31. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Region (2021-2026) Table 34. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Region (2027-2032) Table 36. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Market Share by Country (2021-2026) Table 39. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Market Share by Country (2027-2032) Table 41. Takeda Pharmaceutical Company Company Information Table 42. Takeda Pharmaceutical Company Business Overview Table 43. Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 45. Takeda Pharmaceutical Company Recent Development Table 46. Eisai Company Information Table 47. Eisai Business Overview Table 48. Eisai Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eisai Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 50. Eisai Recent Development Table 51. Johnson & Johnson Company Information Table 52. Johnson & Johnson Business Overview Table 53. Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 55. Johnson & Johnson Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. AstraZeneca Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 60. AstraZeneca Recent Development Table 61. Salix Pharmaceuticals Company Information Table 62. Salix Pharmaceuticals Business Overview Table 63. Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 65. Salix Pharmaceuticals Recent Development Table 66. Abbott Laboratories Company Information Table 67. Abbott Laboratories Business Overview Table 68. Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Product Portfolio Table 70. Abbott Laboratories Recent Development Table 71. Research Programs/Design for This Report Table 72. Authors List of This Report Table 73. Secondary Sources Table 74. Primary Sources List of Figures Figure 1. Gastrointestinal Therapeutics and Diagnostics Product Image Figure 2. Global Gastrointestinal Therapeutics and Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Therapeutics and Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Therapeutics and Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Diagnostics Image Figure 8. Therapeutics Image Figure 9. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type (2021-2032) Figure 12. Peptic Ulcer Disease (PUD) Image Figure 13. GI Bleeding Image Figure 14. Gastroenteritis Image Figure 15. Irritable Bowel Syndrome Image Figure 16. Others Image Figure 17. Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application (2021-2032) Figure 20. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostics
  • Therapeutics
Applications
  • Peptic Ulcer Disease (PUD)
  • GI Bleeding
  • Gastroenteritis
  • Irritable Bowel Syndrome
  • Others
Companies covered
  • Takeda Pharmaceutical Company
  • Eisai
  • Johnson & Johnson
  • AstraZeneca
  • Salix Pharmaceuticals
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gastrointestinal Therapeutics and Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gastrointestinal Therapeutics and Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gastrointestinal Therapeutics and Diagnostics Market Dynamics
  1. 2.1 Gastrointestinal Therapeutics and Diagnostics Industry Trends
  2. 2.2 Gastrointestinal Therapeutics and Diagnostics Industry Drivers
  3. 2.3 Gastrointestinal Therapeutics and Diagnostics Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Therapeutics and Diagnostics Industry Restraints
3 Gastrointestinal Therapeutics and Diagnostics Market by Company
  1. 3.1 Global Gastrointestinal Therapeutics and Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global Gastrointestinal Therapeutics and Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global Gastrointestinal Therapeutics and Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global Gastrointestinal Therapeutics and Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global Gastrointestinal Therapeutics and Diagnostics Company Product Type and Application
  6. 3.6 Global Gastrointestinal Therapeutics and Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gastrointestinal Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gastrointestinal Therapeutics and Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gastrointestinal Therapeutics and Diagnostics Market by Type
  1. 4.1 Gastrointestinal Therapeutics and Diagnostics Type Introduction
  2. 4.1.1 Diagnostics
  3. 4.1.2 Therapeutics
  4. 4.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type
  5. 4.2.1 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type (2021-2032)
5 Gastrointestinal Therapeutics and Diagnostics Market by Application
  1. 5.1 Gastrointestinal Therapeutics and Diagnostics Application Introduction
  2. 5.1.1 Peptic Ulcer Disease (PUD)
  3. 5.1.2 GI Bleeding
  4. 5.1.3 Gastroenteritis
  5. 5.1.4 Irritable Bowel Syndrome
  6. 5.1.5 Others
  7. 5.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application
  8. 5.2.1 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Application (2021-2032)
  10. 5.2.3 Global Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application (2021-2032)
6 Gastrointestinal Therapeutics and Diagnostics Regional Value Analysis
  1. 6.1 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gastrointestinal Therapeutics and Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Country, 2025 VS 2032
7 Gastrointestinal Therapeutics and Diagnostics Country-level Value Analysis
  1. 7.1 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gastrointestinal Therapeutics and Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gastrointestinal Therapeutics and Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gastrointestinal Therapeutics and Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company
  2. 8.1.1 Takeda Pharmaceutical Company Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Salix Pharmaceuticals
  26. 8.5.1 Salix Pharmaceuticals Company Information
  27. 8.5.2 Salix Pharmaceuticals Business Overview
  28. 8.5.3 Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  30. 8.5.5 Salix Pharmaceuticals Recent Developments
  31. 8.6 Abbott Laboratories
  32. 8.6.1 Abbott Laboratories Company Information
  33. 8.6.2 Abbott Laboratories Business Overview
  34. 8.6.3 Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Product Portfolio
  36. 8.6.5 Abbott Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst